BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23044365)

  • 21. Borderline ovarian tumours: clinical analysis of 38 cases.
    Behtash N; Modares M; Abolhasani M; Ghaemmaghami F; Mousavi M; Yarandi F; Hanjani P
    J Obstet Gynaecol; 2004 Feb; 24(2):157-60. PubMed ID: 14766453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study.
    Fauvet R; Demblocque E; Morice P; Querleu D; Daraï E
    Ann Surg Oncol; 2012 Mar; 19(3):941-7. PubMed ID: 21879267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Krukenberg tumor of ovary with features of mucinous cystadenocarcinoma.
    Thomas S; Chandi SM
    Indian J Cancer; 1999; 36(2-4):205-7. PubMed ID: 10921229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pelvic washing cytology in serous borderline tumors of the ovary using ThinPrep: are there cytologic clues to detecting tumor cells?
    Sadeghi S; Ylagan LR
    Diagn Cytopathol; 2004 May; 30(5):313-9. PubMed ID: 15108228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Accuracy of frozen section in diagnosis of ovarian tumors].
    Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 1993 Oct; 28(10):601-3, 635. PubMed ID: 8112130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
    Kolosov AE; Novichkov EV
    Arkh Patol; 2003; 65(5):29-32. PubMed ID: 14664145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Elevated Ca 19.9 tumor marker without evidence of malignancy].
    Gonzalez Bosquet E
    Medicina (B Aires); 2007; 67(3):285-6. PubMed ID: 17628919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diversity in size and signal intensity in multilocular cystic ovarian masses: new parameters for distinguishing metastatic from primary mucinous ovarian neoplasms.
    Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
    J Magn Reson Imaging; 2013 Oct; 38(4):794-801. PubMed ID: 23440747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serous and mucinous borderline (low malignant potential) tumors of the ovary.
    Acs G
    Am J Clin Pathol; 2005 Jun; 123 Suppl():S13-57. PubMed ID: 16100867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Struma ovarii: MRI findings.
    Matsuki M; Kaji Y; Matsuo M; Kobashi Y
    Br J Radiol; 2000 Jan; 73(865):87-90. PubMed ID: 10721328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI of endometriotic cysts in association with ovarian carcinoma.
    Tanaka YO; Okada S; Yagi T; Satoh T; Oki A; Tsunoda H; Yoshikawa H
    AJR Am J Roentgenol; 2010 Feb; 194(2):355-61. PubMed ID: 20093596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
    Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
    J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
    Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR.
    Okamoto Y; Tanaka YO; Tsunoda H; Yoshikawa H; Minami M
    J Magn Reson Imaging; 2007 Jul; 26(1):94-9. PubMed ID: 17659568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of magnetic resonance imaging to differentiate between borderline and malignant serous epithelial ovarian tumors.
    Akçay A; Peker AA; Oran Z; Toprak H; Toluk Ö; Balsak S; Badur BA; Gültekin MA
    Abdom Radiol (NY); 2024 Jan; 49(1):229-236. PubMed ID: 37857912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.
    Booth SJ; Turnbull LW; Poole DR; Richmond I
    BJOG; 2008 Jun; 115(7):894-901. PubMed ID: 18485169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on expression of proliferating cell nuclear antigen (PCNA) in ovarian cancer].
    Terauchi F; Ueno R; Tanabe K; Ogura H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Nov; 48(11):1058-62. PubMed ID: 8940694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrous tumours of the ovary: aetiologies and MRI features.
    Montoriol PF; Mons A; Da Ines D; Bourdel N; Tixier L; Garcier JM
    Clin Radiol; 2013 Dec; 68(12):1276-83. PubMed ID: 23937826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.